Furiex Pharmaceuticals (FURX) 104.77 $FURX
Diarrhea Therapeutic Pipeline Review H1 2015 Market Research Report - New at ReportsnReports.com
PRWeb - Sat Jan 31, 3:30AM CST
The report "Diarrhea - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for diarrhea. Diarrhea describes loose, watery stools that occur more repeatedly than usual. The most common cause of diarrhea is the stomach flu. Eating or drinking food or water that contains certain types of bacteria or parasites can also lead to diarrhea. Diarrhea and related complications can cause severe ill health. The most significant cause of severe ill health is loss of water and electrolytes. Signs and symptoms of diarrhea include dehydration, failure to thrive and malnutrition, abdominal pain, borborygmi and perianal erythema. Diarrheal disease may have a negative impact on both physical fitness and mental development. Complete Report is Available @ http://www.reportsnreports.com/reports/328713...-2015.html.
FURX: 104.77 (-1.41), CBSTZ: 0.06 (unch), PFE: 34.64 (-0.23), ASMB: 10.46 (+0.46), PRTK: 26.95 (+0.65), NVS: 102.20 (-0.17)
Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 1:30PM CST
The report "Erectile Dysfunction - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at http://www.rnrmarketresearch.com/erectile-dys...eport.html .
FURX: 104.77 (-1.41), PTN: 0.72 (-0.02), APRI: 1.84 (-0.08)
Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014
M2 - Wed Jan 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/2z3625/community) has announced the addition of the "Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Furiex Pharmaceuticals, Inc. - Galapagos NV - Novan, Inc. Drug Profiles - acorafloxacin - GLPG-1492 - NVN-4428 - SB-204 - Small Molecules to Inhibit Beta Lactamase for Bacterial Infections - Synthetic Peptide for Multi-Drug Resistant Bacterial Infections For more information visit http://www.researchandmarkets.com/research/2z3625/community
FURX: 104.77 (-1.41), AKAO: 11.11 (-0.27)
UNC-Chapel Hill Eshelman School of Pharmacy Receives $100 Million Commitment - the Largest from an Individual in the University's History - from Alumnus Fred Eshelman
PR Newswire - Wed Dec 03, 1:00PM CST
The University of North Carolina at Chapel Hill today announced a $100 million commitment to the UNC Eshelman School of Pharmacy from Fred Eshelman, a 1972 graduate of the school, founder and former CEO of Pharmaceutical Product Development and founding chairman of Furiex Pharmaceuticals. The school was named for Eshelman in 2008.
FURX: 104.77 (-1.41)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 2.98 (unch), FURX: 104.77 (-1.41), SYN: 2.13 (+0.18), IRWD: 15.15 (-0.85), LXRX: 0.89 (unch), AZN: 69.96 (+0.20), TEVA: 56.77 (-0.58)
Synergy Pharma presents plecanatide IBS-C clinical trial results
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 9:11AM CDT
FURX: 104.77 (-1.41), SGYP: 2.98 (unch), ACT: 285.37 (+3.71), IRWD: 15.15 (-0.85), LXRX: 0.89 (unch), SLXP: 152.35 (+3.17), ARDX: 17.14 (+0.71)
Premature Ejaculation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Wed Sep 24, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9p25qq/premature) has announced the addition of the "Premature Ejaculation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Premature Ejaculation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Ejaculation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - SK Chemicals Co., Ltd. - Yungjin Pharm Ind. Co., Ltd. - Plethora Solutions Holdings plc - NeuroHealing Pharmaceuticals Inc. - Furiex Pharmaceuticals, Inc. - Dong-A Socio Group Drug Profiles - tramadol hydrochloride - (lidocaine prilocaine) - dapoxetine hydrochloride - tramadol hydrochloride - onabotulinumtoxin A - DA-8031 - IX-01 - modafinil - NCE-405 - YPE-1706 For more information visit http://www.researchandmarkets.com/research/9p25qq/premature
FURX: 104.77 (-1.41), AGN: 229.49 (+1.87)
Actavis buys Furiex Pharmaceuticals in all-cash transaction
M2 - Thu Jul 03, 6:31AM CDT
Pharmaceutical company Actavis (NYSE:ACT) stated on Wednesday that its Forest Laboratories subsidiary has closed the acquisition of Furiex Pharmaceuticals (NasdaqGS:FURX) in USD1.1bn in cash.
FURX: 104.77 (-1.41), ACT: 285.37 (+3.71)
Salix Pharmaceuticals Surges on Positive IBS Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 5:15PM CDT
Salix Pharmaceuticals, Ltd.'s (SLXP) announced encouraging data from a phase III study on Xifaxan 550 mg.
FURX: 104.77 (-1.41), MDCO: 29.79 (+0.91), HZNP: 16.84 (-0.41), SLXP: 152.35 (+3.17)
Actavis Completes Acquisition of Furiex Pharmaceuticals
PR Newswire - Wed Jul 02, 7:46AM CDT
Actavis plc (NYSE: ACT) today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.
FURX: 104.77 (-1.41), ACT: 285.37 (+3.71), FRX: 99.00 (-0.77)
Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger
Business Wire - Tue Jul 01, 2:15PM CDT
The stockholders of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) voted today at a special meeting of stockholders to adopt the previously announced agreement and plan of merger, dated as of April 27, 2014, providing for the merger of Furiex with an entity now controlled by Forest Laboratories, LLC, a subsidiary of Actavis plc (NYSE: ACT). Actavis completed its acquisition of Forest Laboratories, Inc. on July 1, 2014. The votes cast by Furiex's stockholders in favor of the proposal to adopt the merger agreement represented approximately 79.85% of Furiex's issued and outstanding common stock entitled to vote as of May 29, 2014, the record date for the special meeting.
FURX: 104.77 (-1.41), ACT: 285.37 (+3.71), FRX: 99.00 (-0.77)
Insider Trading Alert - FURX, EGP And FLT Traded By Insiders
at The Street - Fri Jun 13, 9:13AM CDT
Stocks with insider trader activity include FURX, EGP and FLT
FURX: 104.77 (-1.41), EGP: 63.25 (-0.28), FLT: 150.37 (+1.15)
Approvals, Agreements, Name Change, and Partnerships - Analyst Notes on Johnson & Johnson, Furiex Pharmaceuticals, Select Medical, CTI and Hill-Rom
PR Newswire - Fri Jun 13, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), Select Medical Holdings Corporation (NYSE: SEM), CTI BioPharma Corp. (NASDAQ: CTIC) and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3701-100free.
FURX: 104.77 (-1.41), JNJ: 99.62 (+1.18), CTIC: 2.23 (-0.02), SEM: 14.32 (+0.11), HRC: 46.88 (+0.14)
Regal Entertainment Group Announces Proposed Senior Notes Offering
Business Wire - Tue Feb 25, 6:49AM CST
Regal Entertainment Group ("Regal" or the "Company"
(NYSE:RGC) announced today that it plans to offer senior notes due 2022 (the "Notes" in a registered offering. The principal amount, interest rate and certain other terms of the offering will be determined at the time of pricing.
FURX: 104.77 (-1.41), RGC: 23.23 (+1.35)
Diarrhea Therapeutic Pipeline Review H1 2015 Market Research Report - New at ReportsnReports.com
PRWeb - Sat Jan 31, 3:30AM CST
The report "Diarrhea - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for diarrhea. Diarrhea describes loose, watery stools that occur more repeatedly than usual. The most common cause of diarrhea is the stomach flu. Eating or drinking food or water that contains certain types of bacteria or parasites can also lead to diarrhea. Diarrhea and related complications can cause severe ill health. The most significant cause of severe ill health is loss of water and electrolytes. Signs and symptoms of diarrhea include dehydration, failure to thrive and malnutrition, abdominal pain, borborygmi and perianal erythema. Diarrheal disease may have a negative impact on both physical fitness and mental development. Complete Report is Available @ http://www.reportsnreports.com/reports/328713...-2015.html.
FURX: 104.77 (-1.41), CBSTZ: 0.06 (unch), PFE: 34.64 (-0.23), ASMB: 10.46 (+0.46), PRTK: 26.95 (+0.65), NVS: 102.20 (-0.17)
Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 1:30PM CST
The report "Erectile Dysfunction - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at http://www.rnrmarketresearch.com/erectile-dys...eport.html .
FURX: 104.77 (-1.41), PTN: 0.72 (-0.02), APRI: 1.84 (-0.08)
Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014
M2 - Wed Jan 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/2z3625/community) has announced the addition of the "Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Furiex Pharmaceuticals, Inc. - Galapagos NV - Novan, Inc. Drug Profiles - acorafloxacin - GLPG-1492 - NVN-4428 - SB-204 - Small Molecules to Inhibit Beta Lactamase for Bacterial Infections - Synthetic Peptide for Multi-Drug Resistant Bacterial Infections For more information visit http://www.researchandmarkets.com/research/2z3625/community
FURX: 104.77 (-1.41), AKAO: 11.11 (-0.27)
UNC-Chapel Hill Eshelman School of Pharmacy Receives $100 Million Commitment - the Largest from an Individual in the University's History - from Alumnus Fred Eshelman
PR Newswire - Wed Dec 03, 1:00PM CST
The University of North Carolina at Chapel Hill today announced a $100 million commitment to the UNC Eshelman School of Pharmacy from Fred Eshelman, a 1972 graduate of the school, founder and former CEO of Pharmaceutical Product Development and founding chairman of Furiex Pharmaceuticals. The school was named for Eshelman in 2008.
FURX: 104.77 (-1.41)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 2.98 (unch), FURX: 104.77 (-1.41), SYN: 2.13 (+0.18), IRWD: 15.15 (-0.85), LXRX: 0.89 (unch), AZN: 69.96 (+0.20), TEVA: 56.77 (-0.58)
Synergy Pharma presents plecanatide IBS-C clinical trial results
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 9:11AM CDT
FURX: 104.77 (-1.41), SGYP: 2.98 (unch), ACT: 285.37 (+3.71), IRWD: 15.15 (-0.85), LXRX: 0.89 (unch), SLXP: 152.35 (+3.17), ARDX: 17.14 (+0.71)
Premature Ejaculation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Wed Sep 24, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9p25qq/premature) has announced the addition of the "Premature Ejaculation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Premature Ejaculation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Ejaculation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - SK Chemicals Co., Ltd. - Yungjin Pharm Ind. Co., Ltd. - Plethora Solutions Holdings plc - NeuroHealing Pharmaceuticals Inc. - Furiex Pharmaceuticals, Inc. - Dong-A Socio Group Drug Profiles - tramadol hydrochloride - (lidocaine prilocaine) - dapoxetine hydrochloride - tramadol hydrochloride - onabotulinumtoxin A - DA-8031 - IX-01 - modafinil - NCE-405 - YPE-1706 For more information visit http://www.researchandmarkets.com/research/9p25qq/premature
FURX: 104.77 (-1.41), AGN: 229.49 (+1.87)
Actavis buys Furiex Pharmaceuticals in all-cash transaction
M2 - Thu Jul 03, 6:31AM CDT
Pharmaceutical company Actavis (NYSE:ACT) stated on Wednesday that its Forest Laboratories subsidiary has closed the acquisition of Furiex Pharmaceuticals (NasdaqGS:FURX) in USD1.1bn in cash.
FURX: 104.77 (-1.41), ACT: 285.37 (+3.71)
Salix Pharmaceuticals Surges on Positive IBS Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 5:15PM CDT
Salix Pharmaceuticals, Ltd.'s (SLXP) announced encouraging data from a phase III study on Xifaxan 550 mg.
FURX: 104.77 (-1.41), MDCO: 29.79 (+0.91), HZNP: 16.84 (-0.41), SLXP: 152.35 (+3.17)
Actavis Completes Acquisition of Furiex Pharmaceuticals
PR Newswire - Wed Jul 02, 7:46AM CDT
Actavis plc (NYSE: ACT) today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.
FURX: 104.77 (-1.41), ACT: 285.37 (+3.71), FRX: 99.00 (-0.77)
Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger
Business Wire - Tue Jul 01, 2:15PM CDT
The stockholders of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) voted today at a special meeting of stockholders to adopt the previously announced agreement and plan of merger, dated as of April 27, 2014, providing for the merger of Furiex with an entity now controlled by Forest Laboratories, LLC, a subsidiary of Actavis plc (NYSE: ACT). Actavis completed its acquisition of Forest Laboratories, Inc. on July 1, 2014. The votes cast by Furiex's stockholders in favor of the proposal to adopt the merger agreement represented approximately 79.85% of Furiex's issued and outstanding common stock entitled to vote as of May 29, 2014, the record date for the special meeting.
FURX: 104.77 (-1.41), ACT: 285.37 (+3.71), FRX: 99.00 (-0.77)
Insider Trading Alert - FURX, EGP And FLT Traded By Insiders
at The Street - Fri Jun 13, 9:13AM CDT
Stocks with insider trader activity include FURX, EGP and FLT
FURX: 104.77 (-1.41), EGP: 63.25 (-0.28), FLT: 150.37 (+1.15)
Approvals, Agreements, Name Change, and Partnerships - Analyst Notes on Johnson & Johnson, Furiex Pharmaceuticals, Select Medical, CTI and Hill-Rom
PR Newswire - Fri Jun 13, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), Select Medical Holdings Corporation (NYSE: SEM), CTI BioPharma Corp. (NASDAQ: CTIC) and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3701-100free.
FURX: 104.77 (-1.41), JNJ: 99.62 (+1.18), CTIC: 2.23 (-0.02), SEM: 14.32 (+0.11), HRC: 46.88 (+0.14)
Regal Entertainment Group Announces Proposed Senior Notes Offering
Business Wire - Tue Feb 25, 6:49AM CST
Regal Entertainment Group ("Regal" or the "Company"
(NYSE:RGC) announced today that it plans to offer senior notes due 2022 (the "Notes" in a registered offering. The principal amount, interest rate and certain other terms of the offering will be determined at the time of pricing. FURX: 104.77 (-1.41), RGC: 23.23 (+1.35)
